Related Experiment Video
Updated: Jun 4, 2026
14:39
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
Aromatase inhibitors to augment height: continued caution and study required.
1Saban Research Institute, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA. mgeffner@chla.usc.edu
Journal of Clinical Research in Pediatric Endocrinology
|January 29, 2011
Summary
Aromatase inhibitors (AIs) may increase height potential in children by slowing bone maturation. However, extensive research is needed to confirm efficacy and safety in pediatric populations.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
Background:
- Aromatase inhibitors (AIs) block androgen-to-estrogen conversion.
- Estrogen is crucial for growth plate fusion in children.
- AIs are approved for breast cancer but explored off-label for short stature.
Purpose of the Study:
- To evaluate the potential of AIs to enhance height in children.
- To highlight the need for rigorous studies on AI efficacy and safety in pediatric populations.
Main Methods:
- Review of existing research trials on AI use in children.
- Analysis of limited data from Finland and Florida studies.
- Observation of off-label AI use in the United States.
Main Results:
- Limited data suggests potential efficacy in slowing epiphysial maturation.
- Fewer than 110 children globally treated in research protocols by 2008.
- Many children treated off-label in the US, with unknown outcomes.
Conclusions:
- Aromatase inhibitors show promise for increasing height potential in children.
- Significant gaps exist in understanding the long-term efficacy and safety of AIs in pediatric use.
- Well-designed, long-term studies are imperative for pediatric AI application.
Related Concept Videos
01:10Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...